These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 37531032)
21. Update on gepants for the treatment of chronic migraine. Aoh Y; Hou TW; Yang CC; Chang CM; Chen SP; Tsai IJ; Cheng CW; Yang CP J Chin Med Assoc; 2024 Apr; 87(4):350-356. PubMed ID: 38349136 [TBL] [Abstract][Full Text] [Related]
22. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review. Dos Santos JBR; da Silva MRR Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493 [TBL] [Abstract][Full Text] [Related]
23. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795 [TBL] [Abstract][Full Text] [Related]
25. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Croop R; Berman G; Kudrow D; Mullin K; Thiry A; Lovegren M; L'Italien G; Lipton RB Cephalalgia; 2024 Apr; 44(4):3331024241232944. PubMed ID: 38659334 [TBL] [Abstract][Full Text] [Related]
27. The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful? Tfelt-Hansen P; Loder E Headache; 2019 Jan; 59(1):113-117. PubMed ID: 30451300 [No Abstract] [Full Text] [Related]
28. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis. Zhang Z; Shu Y; Diao Y; Du Y; Chen L; Liu Y; Du B Medicine (Baltimore); 2021 Feb; 100(8):e24741. PubMed ID: 33663087 [TBL] [Abstract][Full Text] [Related]
29. Ubrogepant: First Approval. Scott LJ Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557 [TBL] [Abstract][Full Text] [Related]
30. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047 [TBL] [Abstract][Full Text] [Related]
31. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic novelties in migraine: new drugs, new hope? Do TP; Guo S; Ashina M J Headache Pain; 2019 Apr; 20(1):37. PubMed ID: 30995909 [TBL] [Abstract][Full Text] [Related]
33. Real-world efficacy, tolerability, and safety of ubrogepant. Chiang CC; Arca KN; Dunn RB; Girardo ME; Quillen JK; Dodick DW; Starling AJ Headache; 2021 Apr; 61(4):620-627. PubMed ID: 33547676 [TBL] [Abstract][Full Text] [Related]
34. Atogepant for the Preventive Treatment of Migraine. Ailani J; Lipton RB; Goadsby PJ; Guo H; Miceli R; Severt L; Finnegan M; Trugman JM; N Engl J Med; 2021 Aug; 385(8):695-706. PubMed ID: 34407343 [TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548 [TBL] [Abstract][Full Text] [Related]
36. Atogepant: First Approval. Deeks ED Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050 [TBL] [Abstract][Full Text] [Related]